A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Estonia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Estonia147 clinical trials in Tallin, Estonia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
EstoniaThe busiest research cities in the country
What the registry says about research in the country
Clinical investigations focusing on innovative treatments for ulcerative colitis, specifically targeting patients with mild to moderate left-sided manifestations of the condition. The research explores new therapeutic approaches using targeted delivery methods.
These trials aim to evaluate the effectiveness of a new localized treatment approach compared to placebo, potentially offering improved options for patients with inflammatory bowel conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.